|1.||Lin, Herng-Ching: 8 articles (02/2013 - 06/2006)|
|2.||Razvodovsky, Yury E: 6 articles (07/2014 - 01/2007)|
|3.||Kerr, William C: 4 articles (05/2014 - 11/2007)|
|4.||Chen, Chin-Shyan: 4 articles (05/2012 - 11/2008)|
|5.||Razvodovsky, Y E: 3 articles (03/2015 - 01/2007)|
|6.||Ren, Hong: 3 articles (07/2013 - 11/2007)|
|7.||Ye, Yu: 3 articles (02/2011 - 11/2007)|
|8.||Zhu, X P: 2 articles (01/2016 - 01/2016)|
|9.||Luan, R S: 2 articles (01/2016 - 01/2016)|
|10.||Yin, F: 2 articles (01/2016 - 01/2016)|
|1.||Depressive Disorder (Melancholia)
01/01/1993 - "The antidepressant efficacy of both moclobemide and reference drugs was more pronounced in endogenous than in non-endogenous depression, whatever the severity."
09/01/1996 - "In summary, recent data which confirm and extend its comparative therapeutic efficacy and low potential for adverse effects have established moclobemide as an effective treatment in depressive disorders. "
01/01/1995 - "The evidence indicates that moclobemide is effective in typical severe depression with melancholia rather than being limited to less typical subtypes."
09/01/1996 - "Recent clinical trials and meta-analyses have confirmed the efficacy of moclobemide in the treatment of depressive disorders. "
01/01/1995 - "The efficacy of moclobemide has been demonstrated in psychotic and non-psychotic depression, in depression with and without melancholia, in endogenous depression (both unipolar and bipolar), in retarded depression and in agitated depression. "
|2.||Phobic Disorders (Phobia)
09/01/1997 - "In this open, prospective, structured, naturalistic study of the efficacy of long-term treatment in social phobia 93 consecutive outpatients suffering from severe generalized or circumscribed social phobia (median Liebowitz Social Anxiety Scale score 83) and a high degree of concomitant psychiatric disease were administered treatment with moclobemide (712 +/- 75 mg/day at steady state). "
01/01/2001 - "Moclobemide produced a statistically significant, but clinically modest, degree of improvement in social phobia symptoms. "
01/01/1999 - "The efficacy of moclobemide has been shown in social phobia and the effect is more clear cut in patients with more severe symptoms. "
01/01/1994 - "Moclobemide was effective in both major components of social phobia (fear and avoidance). "
06/01/1996 - "The efficacy of moclobemide in social phobia has been demonstrated in short-term treatment for up to 12 weeks in three placebo-controlled studies. "
|3.||Panic Disorder (Panic Attack)
10/01/1997 - "These data suggest moclobemide is a well tolerated and effective treatment for panic disorder."
04/01/2010 - "Improved statistical analysis of moclobemide dose effects on panic disorder treatment."
04/01/2010 - "We reanalyze, with complete data methods, a clinical trial previously reported using LOCF, comparing placebo and five dosage levels of moclobemide in the treatment of outpatients with panic disorder to illustrate the superiority of methods using repeated observations. "
06/01/2002 - "Patients (N = 452) with panic disorder were randomized to placebo or a fixed dose of moclobemide (75, 150, 300, 600, or 900 mg/day). "
06/01/2002 - "Interactive model of therapeutic response in panic disorder: moclobemide, a case in point."
|4.||Major Depressive Disorder (Major Depressive Disorders)
01/01/1997 - "These results do not support moclobemide as an effective treatment of chronic fatigue syndrome in the absence of a major depressive disorder."
08/01/1999 - "Moclobemide in the treatment of major depressive disorder (DSM-3) following traumatic brain injury."
03/01/1997 - "These results provide supporting evidence of the comparable efficacy of moclobemide and fluoxetine and the better tolerability of moclobemide when used in the treatment of major depressive disorder."
03/01/1997 - "The objective of the present study was to compare the safety and efficacy of moclobemide versus fluoxetine in adult patients with major depressive disorder. "
10/01/2006 - "A metaanalysis of clinical trials comparing moclobemide with selective serotonin reuptake inhibitors for the treatment of major depressive disorder."
|5.||Alzheimer Disease (Alzheimer's Disease)
01/01/1992 - "Depression and senile dementia of the Alzheimer type: a role for moclobemide."
01/01/1995 - "Large placebo-controlled studies have shown the activity of moclobemide in the depression that accompanies dementia (such as senile dementia of Alzheimer type). "
08/01/2008 - "Recent randomized controlled trials demonstrated the efficacy of sertraline and moclobemide to treat depression in Alzheimer's disease. "
06/01/2006 - "Recent randomized controlled trials have demonstrated the efficacy of sertraline and moclobemide to treat depression in Alzheimer's disease. "
|5.||Serotonin (5 Hydroxytryptamine)
|6.||Monoamine Oxidase (MAO)
|7.||Monoamine Oxidase Inhibitors (Monoamine Oxidase Inhibitor)
|1.||Drug Therapy (Chemotherapy)
|2.||Seat Belts (Seat Belt)